- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Alveolar nerve.
Displaying page 1 of 1.
EudraCT Number: 2006-002042-11 | Sponsor Protocol Number: 3699 | Start Date*: 2006-07-31 |
Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust | ||
Full Title: “The efficacy of inferior alveolar nerve block and buccal infiltration for pulp anaesthesia in mandibular teeth” | ||
Medical condition: N/A. This work is of direct relevance to everyday general dental practice. The outcomes of this work are likely to influence the way in which paractitioners approach the problem of anaesthetising m... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004741-16 | Sponsor Protocol Number: TRAMAPIMD-001 | Start Date*: 2014-07-25 | ||||||||||||||||||||||||||
Sponsor Name:Ana de Pedro Muñoz | ||||||||||||||||||||||||||||
Full Title: Effect of preoperatory administration of submucous tramadol on the success rate of inferior alveolar nerve block on mandibular molars with irreversible pulpitis | ||||||||||||||||||||||||||||
Medical condition: Anesthetic failure of the inferior alveolar nerve block in mandibular molars with irreversible pulpitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003745-18 | Sponsor Protocol Number: GISG-04 | Start Date*: 2012-05-22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF PREOPERATIVE THERAPY WITH PAZOPANIB (VOTRIENT®) IN HIGH-RISK SOFT TISSUE SARCOMA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: High-risk soft tissue sarcoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006617-32 | Sponsor Protocol Number: 06/Q0605/1 | Start Date*: 2007-05-02 |
Sponsor Name:Kings College Hospital Trust R&D | ||
Full Title: A prospective randomised double blind parallel trial comparing Articaine versus Lignocaine for mandibular dentistry | ||
Medical condition: necessary dental surgery | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001108-11 | Sponsor Protocol Number: EORTC protocol 62033 | Start Date*: 2004-11-08 | |||||||||||
Sponsor Name:European Organisation for the Research and Treatment of Cancer | |||||||||||||
Full Title: A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-bas... | |||||||||||||
Medical condition: Soft Tissue Sarcoma (STS) is a rare group of heterogeneous mesenchymal cancers originating from connective tissue. There are multiple histological subtypes of STS. At present all these subtypes are... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002821-28 | Sponsor Protocol Number: ET20-128 | Start Date*: 2020-12-24 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o... | ||
Medical condition: Metastatic or unresectable advanced rare sarcomas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001861-40 | Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) | Start Date*: 2006-09-21 | |||||||||||
Sponsor Name:SYSTEMS MEDICINE, LLC | |||||||||||||
Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Advanced or metastatic soft tissue sarcoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005294-60 | Sponsor Protocol Number: CRAD001C24114 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter, triple-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis... | |||||||||||||
Medical condition: histological evidence of progressive or metastatic bone or soft tissue sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000987-80 | Sponsor Protocol Number: ET19036 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarc... | |||||||||||||
Medical condition: advanced/metastatic soft tissu sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004272-20 | Sponsor Protocol Number: E7389-E044-207 | Start Date*: 2006-10-23 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27) | |||||||||||||
Medical condition: Advanced and/or metastatic soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004168-30 | Sponsor Protocol Number: STS001 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma | |||||||||||||
Medical condition: Metastatic or advanced soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005726-15 | Sponsor Protocol Number: 217102 | Start Date*: 2022-05-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with... | |||||||||||||
Medical condition: Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004750-15 | Sponsor Protocol Number: AIO-STS-0415 | Start Date*: 2017-10-06 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. | ||||||||||||||||||
Medical condition: advanced or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004385-17 | Sponsor Protocol Number: MEA115921 | Start Date*: 2013-11-22 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving St... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003239-38 | Sponsor Protocol Number: PH-L19TNFDOX2-03/16 | Start Date*: 2017-07-28 | ||||||||||||||||
Sponsor Name:Philogen S.p.A. | ||||||||||||||||||
Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien... | ||||||||||||||||||
Medical condition: Unresectable or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
